Effect of Continuous Prolonged Prone Position Versus Intermittent Daily Prone Position in ARDS
Launched by PONTIFICIA UNIVERSIDAD CATOLICA DE CHILE · Feb 25, 2025
Trial Information
Current as of July 25, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at two different ways to help patients with moderate to severe Acute Respiratory Distress Syndrome (ARDS) who are on a ventilator. Specifically, the researchers want to find out if keeping patients in the prone position (lying on their stomachs) for more than 48 hours (called prolonged prone position) is better for survival compared to shorter sessions of 16 to 24 hours (called intermittent prone position). They will also check if there are any safety issues with the prolonged method compared to the shorter one.
To be part of this study, participants need to be adults aged 18 and older who have been on a ventilator for less than 72 hours and have been diagnosed with moderate to severe ARDS. If eligible, participants will receive prone positioning either for a longer stretch or in daily sessions during their first week of treatment. They will be monitored for up to 90 days to see how they are doing. This research is important as it aims to improve treatment options for patients facing serious breathing challenges.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age ≥ 18 years
- • Endotracheal intubation and mechanical ventilation for less than 72 hours
- * Moderate-severe ARDS defined as:
- • 1. Within 1 week of a known clinical insult or new or worsening respiratory symptoms
- • 2. Bilateral infiltrates not fully explained by effusions, lobar/lung collapse, or nodules
- • 3. Respiratory failure not fully explained by cardiac failure or fluid overload
- • 4. PaO2/FiO2 \< 150 mmHg in supine position
- • Prone positioning has been indicated by the attending physician, OR has already been initiated within the last 16 hours
- Exclusion Criteria:
- • Contraindications for prone positioning such as intracranial pressure \> 20 mmHg, massive hemoptysis, recent tracheal surgery or sternotomy or abdominal surgery with an open wound, recent facial trauma or facial surgery, unstable spine, femur, or pelvic fractures, or a single anterior chest tube with air leaks
- • Patient on extracorporeal membrane oxygenation (ECMO) before randomization
- • Chronic respiratory failure requiring oxygen therapy or non-invasive ventilation (NIV)
- • Known pregnancy
- • Anticipating withdrawal of life support or shift to palliative care
About Pontificia Universidad Catolica De Chile
Pontificia Universidad Católica de Chile is a prestigious academic institution renowned for its commitment to excellence in education, research, and healthcare. As a clinical trial sponsor, the university leverages its extensive expertise in medical sciences to advance innovative research initiatives aimed at improving patient outcomes. With a strong emphasis on ethical standards and scientific rigor, the institution collaborates with multidisciplinary teams to conduct high-quality clinical trials that contribute to the advancement of medical knowledge and the development of effective therapeutic interventions. Its dedication to fostering a culture of inquiry and community engagement positions Pontificia Universidad Católica de Chile as a leader in the field of clinical research in Latin America.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Santiago, , Chile
Santiago, , Chile
Concepción, , Chile
Los ángeles, , Chile
Quilpué, , Chile
Santiago, , Chile
Patients applied
Trial Officials
Alejandro Bruhn, MD, PhD
Principal Investigator
Pontifiia Universidad Catolica de Chile
Rodrigo Cornejo, MD, MBA
Study Director
University of Chile
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported